Official Title
Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals
Brief Summary

COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University Hospital (HUS) had faced a sudden increase of the number of COVID-19-positive patients in serious condition requiring hospitalization. At the same time, many people develop only mild or moderate symptoms. To date, the prognostic factors for the course of SARS-CoV-2 infection are unknown. The primary purpose of the "COVID-HUS" protocol is to investigate viral and host-related factors to understand the pathophysiology of COVID infection and to open the way for new diagnostic, prognostic and therapeutic strategies against SARS CoV-2 . The secondary objectives are - Monitoring of viral replication of SARS-CoV-2 in the blood and respiratory tract in infected patients - Monitoring of the humoral and cellular response directed against SARS-CoV-2 - Identification of factors leading to significant and / or prolonged viral replication of SARS-CoV-2 in the blood or respiratory samples - Evaluation of the benefit of possible treatments implemented following the diagnosis of SARS-CoV-2 infection - Exploration of the B and T immune repertoire sequences targeting SARS-CoV-2 in infected patients - Typing of the HLA system in infected patients

Unknown status
SARS-CoV-2
Eligibility Criteria

Inclusion Criteria:

- Adult and pediatric with suspicion or a confirmed SARS-CoV-2 infection

- Patient who has signed a non-opposition form (or a form signed by a family member or a
support person if the seriousness of the patient's condition and the emergency
situation do not allow it) or who has given his oral agreement to the doctor

Exclusion Criteria:

- Patient's explicit refusal to participate

- Subject deprived of liberty or subject to the protection of justice

- Subject under guardianship or trusteeship

Eligibility Gender
All
Eligibility Age
Minimum: 1 Year ~ Maximum: N/A
Countries
France
Locations

Service de Virologie - Hôpital Civil
Strasbourg, France

Investigator: Samira FAFI-KREMER, PharmD, PhD
Contact: 33.3.69.55.14.38
Samira.fafi-kremer@chru-strasbourg.fr

Investigator:

Contacts

Samira FAFI-KREMER, PharmD, PhD
33.3.69.55.14.38
Samira.fafi-kremer@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR
33 3 88 11 66 90
said.chayer@chru-strasbourg.fr

Samira FAFI-KREMER, PharmD, PhD, Study Director
Laboratoire de Virologie Plateau Technique de Microbiologie

University Hospital, Strasbourg, France
NCT Number
Keywords
SARS-CoV-2
Covid-19
prognostic factors
Genetic factors
T and B cell immune response